Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 July 2022 | Story Leonie Bolleurs | Photo Supplied
Riaz-Seedat
Prof Riaz Seedat, who enrolled for a PhD through the USDP, wishes to create ear, nose, and throat knowledge through his research that is more relevant to the South African setting.

Prof Riaz Seedat is Professor and Head of the Department of Otorhinolaryngology at the University of the Free State (UFS) and in the Free State Department of Health at the Universitas Academic Hospital. It is in this position where he has the opportunity to treat patients, teach students, and conduct research.

As one of the ten academics enrolled in the University Staff Development Programme (USDP), Prof Seedat forms part of the University Capacity Development Programme (UCDP), which seeks to transform academic expertise in the field of global health.

The UFS Office for International Affairs administers the programme, which offers an enriching journey for the group of academics from the University of the Free State (UFS) and the University of Venda (Univen).

In an interview, he revealed the importance of research focused on ENT cases in developing countries. 

How has your background shaped the life and academic path you have chosen? 

During my internship, I had the opportunity to work in ENT. The field sparked great interest in me, so I decided to specialise in it. 

During my training, it became apparent to me that much of the information in the literature was based on research and practices in developed countries and did not reflect the situation in developing countries, where there is a high burden of infectious diseases and presentation of patients with pathology at an advanced stage. My research has been focused on providing a developing country perspective of otorhinolaryngology, particularly with regard to infectious diseases and allergy in the field, creating ENT knowledge that is more relevant to the South African setting. 

What drew you to the USDP project’s call? 

The USDP provides me with the chance to complete my doctorate on recurrent respiratory papillomatosis, a disease that is characterised by recurrent wart-like growths on the surface of the vocal cords or tissue around the vocal cords.

In our context, this affects mostly children and there is a relatively high prevalence of this condition here in the Free State. Research through this PhD will expand knowledge on the diagnosis and management of the condition. 

Please tell us more about your research. 

I have identified that in South Africa, recurrent respiratory papillomatosis, which is caused by the human papillomavirus, occurs more commonly in children than in Europe, where mostly adults are affected. In future, I would like my research to find factors that can help to identify which patients with recurrent respiratory papillomatosis will develop more severe disease, in order to better treat them. 

I have also done work on infectious diseases such as HIV and ENT, describing the impact of HIV in the different ENT conditions we see. 

With regard to allergic rhinitis, we have studied the impact of the condition on patients’ quality of life and are identifying the most frequent allergens present in our setting here in the Free State.

Did the pandemic impact your research?

Yes, it did. Being a full-time clinician for the Free State Department of Health meant that we had to dedicate more time towards managing the pandemic. This has affected patient care and the research we do on the patients. Many patients could not access healthcare facilities because of the lockdown, impacting their treatment, as well as research being carried out. 

Global health is one of the critical issues for the future of the human species, especially in Africa, where both infectious and non-communicable diseases threaten development. What will your project contribute to the field? 

Many of the conditions I am researching are as a result of infectious diseases. Unfortunately, these are conditions that are often neglected as they occur mainly in developing countries. The research will positively impact society through the care and treatment of patients with the condition. 

What are your future career plans? How will a PhD qualification assist you in reaching these goals?

A PhD will help me obtain a better understanding of research content and methodologies. I believe that a PhD will also equip me with the knowledge to better supervise individuals who wish to further their academic careers and do their own PhDs. 

What is your advice for aspiring PhD candidates?

I would advise someone who wishes to complete a PhD to work on a topic that they have a great interest in, because it is a task that will take much of your time. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept